8-K: Nexalin Boosts ATM Offering to $10M

Nexalin Technology, Inc. increased its at-the-market equity offering program to allow for the sale of up to $10 million in common stock.

Summary

• Nexalin Technology, Inc. entered into Amendment No. 2 to its Equity Distribution Agreement with Maxim Group LLC on October 15, 2025.
• The amendment increases the maximum aggregate offering price of common stock that may be issued and sold through the at-the-market (ATM) program from $3,100,000 to $10,000,000.
• As of October 15, 2025, approximately $4,273,859 in aggregate amount of shares are available for sale under the ATM Program.
• The shares will be issued pursuant to the company's effective shelf registration statement on Form S-3 (File No. 333-286711) dated April 29, 2025, and a new prospectus supplement dated October 15, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The increased ATM facility provides Nexalin Technology with significantly enhanced flexibility to raise capital, which is crucial for funding operations and strategic initiatives. While potential dilution is a negative, the ability to secure funding is a strong positive for the company's operational continuity and growth prospects.

Positives

• The company gains increased flexibility and capacity to raise capital, with the ATM program limit expanding from $3.1 million to $10 million.
• The at-the-market offering mechanism provides a cost-effective and efficient way to access capital as needed, without the complexities of a traditional underwritten offering.

Negatives

• The increase in the ATM program limit to $10 million introduces a greater potential for dilution for existing shareholders as more common stock can be sold into the market.
• The actual proceeds from the ATM program will depend on market conditions and the company's stock price at the time of sale, which could be volatile.

Risks

• Potential for significant shareholder dilution due to the increased capacity to issue and sell common stock through the ATM program.
• Market conditions and the company's stock price could negatively impact the amount of capital that can be raised and the average price per share, potentially leading to lower-than-expected proceeds.
• The company's ability to utilize the full $10 million depends on satisfying eligibility and transaction requirements for Form S-3, as well as board authorizations.

Future Outlook

The company intends to continue utilizing its at-the-market equity distribution program to raise capital by selling shares of common stock from time to time, up to the newly increased aggregate offering price of $10,000,000.

Management Comments

• Mark White, Chief Executive Officer, signed the Form 8-K on behalf of Nexalin Technology, Inc.
• Ritesh Veera, Co-Head of Investment Banking, signed the Amendment No. 2 on behalf of Maxim Group LLC.

Industry Context

At-the-market (ATM) offerings are a common and flexible capital-raising tool for publicly traded companies, particularly those seeking to fund ongoing operations, research and development, or general corporate purposes without the upfront costs and market timing risks associated with traditional underwritten offerings. This move aligns with a strategy to maintain financial flexibility.

Comparison to Industry Standards

• This is a standard capital-raising mechanism frequently employed by small to mid-cap companies, particularly in the technology and biotechnology sectors, to access capital efficiently.
• The increase in the ATM facility size is a common practice as companies' funding needs evolve or as their market capitalization grows, allowing for greater financial flexibility compared to smaller, more restrictive facilities.

Stakeholder Impact

• Shareholders: Face potential dilution of their ownership stake as more common stock can be issued and sold under the expanded ATM program. The impact will depend on the volume and pricing of future sales.
• Company: Gains greater financial flexibility and access to capital, which can support ongoing operations, research and development, and other strategic initiatives without incurring significant debt.

Next Steps

• The company may continue to sell shares of its common stock from time to time through Maxim Group LLC under the ATM program, up to the new $10,000,000 limit.
• The company will file prospectus supplements as needed to reflect ongoing sales under the ATM program.

Key Dates

Recommendation

The increased at-the-market offering provides Nexalin Technology with greater flexibility to raise capital, which is a positive for funding operations and strategic initiatives. However, the potential for significant shareholder dilution from the sale of up to $10 million in common stock warrants a cautious 'hold' recommendation. Investors should monitor the pace and pricing of these sales and assess the company's use of proceeds before making further investment decisions. Without additional financial performance data or strategic announcements, a neutral stance is prudent.

Keywords

Nexalin Technology, NXL, ATM offering, equity distribution agreement, capital raise, common stock, Maxim Group, SEC filing, 8-K, dilution